Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical ...

Samsung Bioepis Co. and Teva Pharmaceutical Industries (TEVA have entered into a license, development and commercialization agreement ...

Pharmaceutical Industries announced that the companies have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis’ biosimilar to Soliris in the United States ...

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH),atypical hemolytic uremic syndrome (aHUS)andgeneralized myasthenia gravis (gMG)in the U ...

Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...

Amgen’s biosimilar was approved in Europe under the Bekemv brand name last year and competes in the EU with the Samsung Bioepis rival sold as Epysqli. Samsung Bioepis has also filed for approval ...

In July 2024, Samsung Bioepis received US Food and Drug Administration (FDA) approval for Epysqli (eculizumab-aagh), a biosimilar to AstraZeneca acquiree Alexion Pharmaceuticals’ Soliris ...

The clinical safety of eculizumab biosimilars is paramount. Two such biosimilars have been identified: Bkemv (eculizumab-aeeb) and Epysqli (eculizumab-aagh). On 29 May 2024, the U.S. FDA granted ...

For more information, or to register for this event, visit The New Era of CDx in Oncology: Adapting Clinical Research Strategy to Evolving Regulations.

Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") today announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a public offering price of $3.50 per ...

U.S. President-elect Donald Trump will not go to jail or face any other punishment for his criminal conviction stemming from hush money paid to a porn star, a judge ruled on Friday but said Trump ...